MXPA04009012A - Combinacion de inhibidor ofa cdk y 5 fu para el tratamiento de cancer. - Google Patents

Combinacion de inhibidor ofa cdk y 5 fu para el tratamiento de cancer.

Info

Publication number
MXPA04009012A
MXPA04009012A MXPA04009012A MXPA04009012A MXPA04009012A MX PA04009012 A MXPA04009012 A MX PA04009012A MX PA04009012 A MXPA04009012 A MX PA04009012A MX PA04009012 A MXPA04009012 A MX PA04009012A MX PA04009012 A MXPA04009012 A MX PA04009012A
Authority
MX
Mexico
Prior art keywords
cdk inhibitor
cancer
treatment
combination ofa
prodrug
Prior art date
Application number
MXPA04009012A
Other languages
English (en)
Inventor
James Mcclue Steven
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0206203A external-priority patent/GB0206203D0/en
Priority claimed from GB0300295A external-priority patent/GB0300295D0/en
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Publication of MXPA04009012A publication Critical patent/MXPA04009012A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un primer aspecto de la presente invencion, se refiere a una combinacion que comprende un inhibidor CDK y 5-FU, o un profarmaco de los mismos. Un segundo aspecto de la presente invencion, se refiere a un producto farmaceutico que comprende un inhibidor CDK y 5-FU, o un profarmaco de los mismos, en la forma de una preparacion combinada para utilizarse en una terapia simultanea, en secuencias o por separado. Un tercer aspecto de la presente invencion, se refiere a un metodo para tratar un padecimiento proliferativo, en donde el metodo comprende administrar a un sujeto en forma simultanea, en secuencias o por separado un inhibidor CDK y 5-FU, o un profarmaco de los mismos.
MXPA04009012A 2002-03-15 2003-03-14 Combinacion de inhibidor ofa cdk y 5 fu para el tratamiento de cancer. MXPA04009012A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0206203A GB0206203D0 (en) 2002-03-15 2002-03-15 Use
GB0300295A GB0300295D0 (en) 2003-01-07 2003-01-07 Use
PCT/GB2003/001076 WO2003077999A1 (en) 2002-03-15 2003-03-14 Combination ofa cdk inhibitor and 5-fu for the treatment of cancer

Publications (1)

Publication Number Publication Date
MXPA04009012A true MXPA04009012A (es) 2004-12-07

Family

ID=28043400

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04009012A MXPA04009012A (es) 2002-03-15 2003-03-14 Combinacion de inhibidor ofa cdk y 5 fu para el tratamiento de cancer.

Country Status (7)

Country Link
US (1) US20050164976A1 (es)
EP (1) EP1485168A1 (es)
JP (1) JP2005526086A (es)
CN (1) CN1652844A (es)
AU (1) AU2003216810A1 (es)
MX (1) MXPA04009012A (es)
WO (1) WO2003077999A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0012528D0 (en) * 2000-05-23 2000-07-12 Univ Palackeho Triterpenoid derivatives
ATE418333T1 (de) * 2002-11-06 2009-01-15 Cyclacel Ltd Kombination aus docetaxel und einem cdk-hemmer
GB0328180D0 (en) * 2003-12-04 2004-01-07 Cyclacel Ltd Combination
WO2009014642A1 (en) * 2007-07-19 2009-01-29 Amgen Inc. Combination of a de novo purine biosynthesis inhibitor and a cyclin dependent kinase inhibitor for the treatment of cancer
JP5579715B2 (ja) * 2008-07-29 2014-08-27 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ ｃｄｋ阻害剤および抗悪性腫瘍剤を含む治療用組合せ
JP6286421B2 (ja) 2012-05-15 2018-02-28 サイクラセル リミテッド サパシタビン及びセリシクリブの投与レジメン

Also Published As

Publication number Publication date
CN1652844A (zh) 2005-08-10
US20050164976A1 (en) 2005-07-28
EP1485168A1 (en) 2004-12-15
WO2003077999A1 (en) 2003-09-25
JP2005526086A (ja) 2005-09-02
AU2003216810A1 (en) 2003-09-29

Similar Documents

Publication Publication Date Title
MXPA05004919A (es) Composicion farmaceutica que comprende un inhibidor cdk y gemcitabina.
HK1046093A1 (en) Docetaxel in combination with rhumab her2 for the treatment of cancers.
WO2005058233A3 (en) Methods for treatment of acute pancreatitis
WO2004006842A3 (en) Combinations of drugs for the treatment of neoplasms
MXPA03010121A (es) Terapia de combinacion que utiliza anticuerpos anti-receptor de factor de crecimiento epidermico y agentes anti-hormonales.
TW200518752A (en) Combinations of drugs for the treatment of neoplasms
WO2006110175A3 (en) Combined treatment with bortezomib and an epidermal growth factor receptor kinase inhibitor
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
TW200633700A (en) Methods of using temozolomide formulation intrathecally in the treatment of cancers
HK1071310A1 (en) Combination therapy for the treatment of cancer
WO2005118601A3 (en) Sulfonylethyl phosphorodiamidates for use in the treatment of cancer
WO2004045593A3 (en) Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
WO2005000211A3 (en) Method for treating diseases using hsp90-inhibiting agents in combination with platinum coordination complexes
GB0328180D0 (en) Combination
MXPA05008583A (es) Terapia de combinacion de zd6474 con 5-fu y/o cpt-11.
TW200608959A (en) Treatment with oxaliplatin and an egfr-inhibitor
MXPA04009012A (es) Combinacion de inhibidor ofa cdk y 5 fu para el tratamiento de cancer.
MXPA05004917A (es) Combinacion que comprende docetaxel y un inhibidor cdk.
MXPA05004920A (es) Combinacion que comprende un inhibidor cdk y cisplatin.
MXPA04009396A (es) Combinacion que comprende un inhibidor cdk y doxorubicina.
BR0316029A (pt) Combinação
WO2007054725A3 (en) Combination of a cdk-inhibitor and a hdac-inhibitor
AU2002319223A1 (en) Medicament for treating tumours and their metastases using a binding molecule against bone-sialoprotein
IL164356A (en) Use of alpha- bromo or alpha-chloro acryloyl distamycin derivatives in the preparation of medicaments for treating cancer
MXPA05013827A (es) Composiciones que comprenden zd6126 junto con 5-fu, cpt-11 o 5-fu y cpt-11, que tienen actividad de dano vascular, para tratar cancer colorectal e. g.